Arexvy Kit
Product Images NDC 58160-894

15 FDA label images from Glaxosmithkline Biologicals Sa · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Arexvy (NDC 58160-894). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Biologicals Sa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Arexvy Spl Graphic 01)

Figure 1 (Arexvy Spl Graphic 01)
An instructional diagram showing a syringe drawing liquid from a vial labeled as the Adjuvant Suspension Component, indicating preparation of the respiratory syncytial virus vaccine recombinant, adjuvanted kit.*
FDA Label Image

Figure 2 (Arexvy Spl Graphic 02)

Figure 2 (Arexvy Spl Graphic 02)
An instructional diagram showing a syringe positioned above a vial labeled '2,' which contains a lyophilized antigen component (powder). A downward arrow indicates that the syringe is to be inserted into the vial for reconstitution or preparation.*
FDA Label Image

Figure 3 (Arexvy Spl Graphic 03)

Figure 3 (Arexvy Spl Graphic 03)
An instructional diagram showing a hand holding a syringe that is being twisted or unlocked from a vial. The image illustrates a step in preparing a vaccine dose, specifically for Arexvy, a respiratory syncytial virus vaccine recombinant, adjuvanted kit by GlaxoSmithKline Biologicals SA.*
FDA Label Image

Figure 4 (Arexvy Spl Graphic 04)

Figure 4 (Arexvy Spl Graphic 04)
An instructional diagram showing a syringe being filled with reconstituted vaccine from a vial labeled with a number 2. A downward arrow indicates the direction of fluid transfer from vial to syringe. This likely illustrates preparation steps for the Arexvy respiratory syncytial virus vaccine recombinant, adjuvanted kit.*
FDA Label Image

Figure 1 (Arexvy Spl Graphic 05)

Figure 1 (Arexvy Spl Graphic 05)
The image shows a packaging label for Arexvy, a Respiratory Syncytial Virus Vaccine, Adjuvanted in a kit form by GlaxoSmithKline Biologicals SA. The label includes instructions to combine one vial of lyophilized antigen component with one vial of adjuvant suspension component before use. It specifies the vaccine is for individuals 60 years of age and older and contains 10 doses each of the adjuvant suspension component and lyophilized antigen component.*
FDA Label Image

Figure 2 (Arexvy Spl Graphic 06)

Figure 2 (Arexvy Spl Graphic 06)
Label from a vial of Arexvy Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted. This is the lyophilized antigen component vial, part of a two-vial kit. Label states it must be reconstituted with the adjuvant suspension and not used alone. Manufacturer is GlaxoSmithKline Biologicals.*
FDA Label Image

Figure 3 (Arexvy Spl Graphic 07)

Figure 3 (Arexvy Spl Graphic 07)
Label for Arexvy Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted Adjuvant Suspension Component. The label states it is NOT TO BE USED ALONE and instructs to add to 1 vial of Lyophilized Antigen Component to form Arexvy. Manufactured by GlaxoSmithKline Biologicals SA. Includes NDC 58160-744-03 and barcode.*
FDA Label Image

Figure 4 (Arexvy Spl Graphic 08)

Figure 4 (Arexvy Spl Graphic 08)
An instructional illustration showing a syringe drawing vaccine from a vial labeled 'Reconstituted Vaccine.' The syringe is positioned beneath the vial, indicating the step of vaccine preparation for administration in the kit form of Arexvy Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted.*
FDA Label Image

Arexvy 10 Dose Carton (Arexvy Spl Graphic 09)

Arexvy 10 Dose Carton (Arexvy Spl Graphic 09)
Label for Arexvy Respiratory Syncytial Virus Vaccine, Recombinant, Adjuvanted kit by GlaxoSmithKline Biologicals SA. The label includes NDC 58160-848-11 and states it is for adults 60 years and older or adults 18 to 59 years at increased risk of lower respiratory tract disease caused by RSV. The kit contains 10 doses with 10 vials of adjuvant suspension and 10 vials of lyophilized antigen component, providing 0.5 mL per reconstituted dose.*
FDA Label Image

Arexvy Antigen Vial Label (Arexvy Spl Graphic 10)

Arexvy Antigen Vial Label (Arexvy Spl Graphic 10)
Label for Arexvy Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted, lyophilized antigen component vial 2 of 2. The label instructs not to use this component alone and to reconstitute with adjuvant suspension to form the vaccine. Contains dosage information for a 0.5-mL single dose after reconstitution, manufactured by GlaxoSmithKline Biologicals SA.*
FDA Label Image

Arexvy Adjuvant Vial Label (Arexvy Spl Graphic 11)

Arexvy Adjuvant Vial Label (Arexvy Spl Graphic 11)
Label from the Arexvy Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted kit showing the Adjuvant Suspension Component vial. The label indicates it is vial 1 of 2 in the kit, includes instructions not to use alone, and directs to add to one vial of lyophilized antigen component to form Arexvy. Manufactured by GlaxoSmithKline Biologicals SA.*
FDA Label Image

Arexvy 1 Dose Carton (Arexvy Spl Graphic 12)

Arexvy 1 Dose Carton (Arexvy Spl Graphic 12)
Label for Arexvy Respiratory Syncytial Virus Vaccine, Adjuvanted, a vaccine kit by GlaxoSmithKline Biologicals SA. The label notes the combination of one vial of lyophilized antigen component and one prefilled syringe of adjuvant suspension component for use. It specifies use for adults 60 years and older, and for those 18 to 59 years at increased risk of lower respiratory tract disease caused by RSV. Contents include one vial of lyophilized antigen and one syringe of adjuvant suspension, for intramuscular use. Needle is not included.*
FDA Label Image

Arexvy Antigen Vial Label (Arexvy Spl Graphic 13)

Arexvy Antigen Vial Label (Arexvy Spl Graphic 13)
Arexvy Lyophilized Antigen Component label showing NDC 58160-719-03. The label instructs reconstitution with Adjuvant Suspension to form Respiratory Syncytial Virus Vaccine, Adjuvanted. Manufactured by GlaxoSmithKline Biologicals SA. Dosage specifies a single 0.5 mL dose after reconstitution. The label includes storage and lot information fields.*
FDA Label Image

Arexvy Adjuvant Syringe Label (Arexvy Spl Graphic 14)

Arexvy Adjuvant Syringe Label (Arexvy Spl Graphic 14)
Label for the Adjuvant Suspension Component of Arexvy Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted kit by GlaxoSmithKline Biologicals. The label includes cautions such as "NOT TO BE USED ALONE" and instructions to add it to 1 vial of Lyophilized Antigen Component to form the complete vaccine. It has placeholders for lot and expiration dates and displays the NDC 58160-749-07.*
FDA Label Image

Arexvy 10 Dose Carton (Arexvy Spl Graphic 15)

Arexvy 10 Dose Carton (Arexvy Spl Graphic 15)
The Arexvy Respiratory Syncytial Virus Vaccine, Adjuvanted kit label from GlaxoSmithKline Biologicals SA shows NDC 58160-894-15 and highlights it is Rx only. The label instructs to combine one vial of lyophilized antigen component with one prefilled syringe of adjuvant suspension component. It includes 10 vials and 10 syringes for 10 doses, intended for intramuscular use in adults 60 years and older, and 18-59 years at increased risk of lower respiratory tract disease caused by RSV. Needles are not included, and TIP-LOK syringes are for use with Luer Lock compatible needles.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.